信达生物近日在港交所发布公告,截至2024年12月31日止年度,公司总收入达人民币94.219亿元,较上年增长51.8%。收入主要由产品销售收入和授权费收入构成,显示公司在生物医药领域的持续扩张与强劲业绩表现。免责声明:本文内容由开放的智能模型自动生成,仅供参考。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.